Core Viewpoint - The company reported significantly better-than-expected performance in Q3 2025, with an upward revision of the full-year revenue guidance to a 17%-18% year-over-year growth rate [1][4]. Financial Performance - For the first nine months of 2025, the company achieved a revenue of RMB 32.86 billion (+18.6% YoY), with continuous operating revenue at RMB 32.45 billion (+22.5% YoY) and adjusted Non-IFRS net profit of RMB 10.54 billion (+43.4% YoY), all exceeding market expectations [2]. - In Q3 2025, revenue reached RMB 12.06 billion (+15.3% YoY, +8.2% QoQ), with continuous operating revenue at RMB 12.04 billion (+19.7% YoY, +9.4% QoQ) [2]. - The adjusted Non-IFRS net profit for Q3 2025 was RMB 4.22 billion (+42.0% YoY, +16.1% QoQ), with a net profit margin increasing to 35.0% (+6.6 percentage points YoY, +2.4 percentage points QoQ) [2]. Business Segments - The small molecule D&M revenue and TIDES business continued to drive revenue growth and improve gross margins in Q3 2025, with TIDES revenue growing by 92.1% YoY [3]. - The Wuxi Chemistry segment achieved a revenue growth of 22.7% YoY, supported by the strong performance of small molecule D&M and TIDES [3]. Order Backlog and Guidance - The order backlog reached a record high of RMB 59.88 billion (+41.2% YoY), with new order growth in Q3 2025 accelerating to around 18% [4]. - The company raised its 2025 continuous operating revenue guidance from RMB 42.5-43.5 billion to RMB 43.5-44 billion [4]. Strategic Developments - The company is divesting non-core businesses to enhance profit margins, having signed an agreement to sell its clinical CRO and SMO subsidiaries [5]. - Early-stage business recovery is noted, with positive signals from clients and a return to growth in laboratory testing services [5]. Market Position and Valuation - The company maintains a "Buy" rating and has raised its target prices for Hong Kong and A-shares to HKD 134.5 and RMB 124.4, respectively, based on updated financial information [6].

Core Viewpoint - Recently, Shanghai WuXi AppTec New Drug Development Co., Ltd. has undergone a significant change in its registered capital, reducing from approximately 12.46 billion RMB to about 2.58 billion RMB, representing a decrease of approximately 79% [1][1]. Company Summary - The company was established in April 2002 and is wholly owned by WuXi AppTec (603259) [1]. - The legal representative of the company is Zhang Chaohui [1]. - The business scope includes health consulting, pharmaceutical consulting, and self-owned real estate development [1].

Core Viewpoint - Goldman Sachs anticipates a positive market reaction to WuXi AppTec's strong performance and new order momentum, despite concerns regarding the slowdown in TIDES (oligonucleotide and peptide) order reserve growth [1] Financial Performance - WuXi AppTec reported third-quarter revenue of 12.1 billion RMB, representing a year-on-year increase of 15.3% [1] - The management has raised the full-year revenue guidance for 2025 to 43.5 to 44 billion RMB, up from the previous guidance of 42.5 to 43.5 billion RMB [1] - The revenue growth guidance for continuing operations has been adjusted to an annual increase of 17% to 18%, up from the previous range of 13% to 17% [1] Capital Expenditure - The capital expenditure for the third quarter was 1.47 billion RMB, with a total of 3.57 billion RMB for the first nine months [1] - The full-year capital expenditure budget has been revised down to 5.5 to 6 billion RMB, from the earlier estimate of 7 to 8 billion RMB, due to longer-than-expected settlement periods for some projects [1]

Core Viewpoint - WuXi AppTec has announced the sale of its clinical service subsidiaries, aiming to focus on its CRDMO business model and enhance global capabilities while reporting strong financial performance in the first three quarters of the year [1][2][9]. Group 1: Asset Sale Details - WuXi AppTec plans to sell 100% equity of its subsidiaries, Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jishi Pharmaceutical Technology Co., Ltd., to Hillhouse Capital for a base price of 2.8 billion yuan [1]. - The two subsidiaries generated approximately 1.16 billion yuan in revenue and 90 million yuan in net profit for the first three quarters of 2025, accounting for 3.5% and 0.7% of WuXi AppTec's total revenue and net profit, respectively [2]. Group 2: Strategic Focus - The sale is part of WuXi AppTec's strategy to concentrate on its CRDMO business model, which includes drug discovery, laboratory testing, and process development, thereby providing financial support for global capacity expansion [2][7]. - The company has been optimizing its business structure over the past year, including the sale of its WuXi ATU business in the U.S. and U.K., which contributed 1.32 billion yuan in revenue for 2024 [3]. Group 3: Financial Performance - For the first three quarters of 2025, WuXi AppTec reported revenue of 32.857 billion yuan, a year-on-year increase of 18.61%, and a net profit of 12.076 billion yuan, up 84.84% [9]. - The chemical segment was the largest revenue contributor, generating 25.98 billion yuan, a 29.3% increase year-on-year [10]. - The U.S. market remains the primary revenue source, with 22.15 billion yuan in revenue, reflecting a 31.9% growth [11].

Investment Rating - The report maintains an "Outperform" rating for the company, expecting a relative benchmark index increase of over 10% in the next 12-18 months [20]. Core Insights - The company has raised its full-year performance guidance, anticipating ongoing business revenue growth to shift from 13-17% to 17-18% [4][8]. - As of September 2025, the company's ongoing business orders reached RMB 59.88 billion, reflecting a year-on-year increase of 41.2% [4][8]. - Revenue forecasts for 2025-2027 are projected at RMB 44.02 billion, RMB 48.85 billion, and RMB 55.90 billion, with growth rates of 12.2%, 11.0%, and 14.0% respectively [4][8]. - Net profit attributable to shareholders is expected to be RMB 16.19 billion, RMB 14.68 billion, and RMB 16.88 billion for the same period, with growth rates of 71.3%, -9.3%, and 15.0% respectively [4][8]. - The company’s EPS is projected at RMB 5.42, RMB 4.92, and RMB 5.66 for 2025-2027 [4][8]. Financial Summary - The total revenue for 2023 is reported at RMB 40.34 billion, with a slight increase of 2.5% [3]. - The net profit for 2023 is RMB 9.61 billion, showing a growth of 9.0% [3]. - The company’s net asset return rate is expected to be 21.3% in 2025, with a PE ratio of 19.14 [3][4]. - The small molecule CDMO business reported revenue of RMB 14.24 billion in the first three quarters of 2025, a year-on-year increase of 14.1% [4][8]. - The TIDES business experienced significant growth, with revenue reaching RMB 7.84 billion, up 121.1% year-on-year [4][8]. Business Developments - The company has completed the capacity expansion for polypeptides, with solid-phase synthesis reactors exceeding 100,000L by September 2025 [4][8]. - An agreement was reached to sell 100% of its China clinical service research business for RMB 2.8 billion, while maintaining stable growth in its biological business [4][8]. - The laboratory analysis and testing revenue was RMB 2.96 billion, reflecting a 2.7% year-on-year increase [4][8].

Core Viewpoint - Daiwa's research report indicates that WuXi AppTec's Q3 revenue increased by 15% year-on-year to 12.1 billion yuan, and net profit rose by 53% year-on-year to 3.5 billion yuan, exceeding market expectations by 5% and 15% respectively [1] Financial Performance - Revenue growth was primarily driven by a 23% year-on-year increase in the chemical business and a 7.8 percentage point rise in gross margin [1] - The company has raised its full-year revenue guidance for continuing operations from a growth of 13-17% to a growth of 17-18% [1] - The total revenue target for the year has been adjusted from 42.5-43.5 billion yuan to 43.5-44 billion yuan [1] Analyst Rating - Daiwa maintains a "Buy" rating for WuXi AppTec, based on the upward revision of gross margin forecasts [1] - The target price has been increased from 134 HKD to 138 HKD [1]

Core Viewpoint - Daiwa's report indicates that WuXi AppTec (603259)(02359) achieved a 15% year-on-year revenue increase in Q3, reaching 12.1 billion RMB, and a 53% year-on-year net profit increase to 3.5 billion RMB, exceeding market expectations by 5% and 15% respectively [1] Financial Performance - Q3 revenue increased by 15% year-on-year to 12.1 billion RMB [1] - Q3 net profit increased by 53% year-on-year to 3.5 billion RMB [1] - Chemical business revenue grew by 23% year-on-year [1] - Gross margin improved by 7.8 percentage points year-on-year [1] Guidance and Target Adjustments - The company raised its full-year revenue guidance for continuing operations from a growth of 13-17% to a growth of 17-18% [1] - The total revenue target for the year was adjusted from 42.5-43.5 billion RMB to 43.5-44 billion RMB [1] Analyst Rating and Price Target - Daiwa maintains a "Buy" rating for the company [1] - The target price was increased from 134 HKD to 138 HKD based on the revised gross margin forecast [1]

Core Viewpoint - Daiwa's report indicates that WuXi AppTec (02359) experienced a 15% year-on-year increase in revenue for Q3, reaching 12.1 billion RMB, and a 53% increase in net profit to 3.5 billion RMB, surpassing market expectations by 5% and 15% respectively [1] Financial Performance - Q3 revenue increased by 15% year-on-year to 12.1 billion RMB [1] - Net profit rose by 53% year-on-year to 3.5 billion RMB [1] - Chemical business revenue grew by 23% year-on-year [1] - Gross margin improved by 7.8 percentage points year-on-year [1] Guidance and Ratings - The company raised its full-year revenue guidance for continuing operations from a growth of 13-17% to 17-18% [1] - The total revenue target for the year was adjusted from 42.5-43.5 billion RMB to 43.5-44 billion RMB [1] - Daiwa maintains a "Buy" rating and has increased the target price from 134 HKD to 138 HKD based on the revised gross margin forecast [1]

Core Viewpoint - Goldman Sachs anticipates a positive market reaction to WuXi AppTec's strong performance and new order momentum, despite concerns regarding the slowdown in TIDES order reserve growth [1] Financial Performance - WuXi AppTec reported third-quarter revenue of 12.1 billion RMB, representing a year-on-year increase of 15.3%, or a 19.7% increase when considering continuing operations [1] - The TIDES business experienced a significant year-on-year growth of 91%, contributing to 23% of total revenue [1] Target Price and Valuation - Goldman Sachs set a 12-month target price of 109.6 HKD for WuXi AppTec's Hong Kong stock, based on a forward price-to-earnings ratio of 18 times, while the target price for the Shanghai stock is 105.6 RMB [1] Revenue Guidance - WuXi AppTec's management raised the full-year revenue guidance for 2025 to 43.5 to 44 billion RMB, up from the previous guidance of 42.5 to 43.5 billion RMB [1] - The revenue growth guidance for continuing operations was also increased to 17% to 18% year-on-year, compared to the previous range of 13% to 17% [1] Capital Expenditure and Cash Flow - The third-quarter capital expenditure was 1.47 billion RMB, with a total of 3.57 billion RMB for the first nine months [1] - The full-year capital expenditure budget was revised down to 5.5 to 6 billion RMB from the previous estimate of 7 to 8 billion RMB due to longer-than-expected project settlement cycles [1] - The free cash flow guidance was raised to 8 to 8.5 billion RMB, up from the previous range of 5 to 6 billion RMB [1] - Management reiterated its commitment to advancing global capacity construction [1]

Core Viewpoint - Goldman Sachs anticipates a positive market reaction to WuXi AppTec's strong performance and new order momentum, despite concerns regarding the slowdown in TIDES order reserve growth [1] Financial Performance - WuXi AppTec reported third-quarter revenue of 12.1 billion RMB, representing a year-on-year increase of 15.3%, or a 19.7% increase when considering continuing operations [1] - The TIDES business experienced a significant year-on-year growth of 91%, contributing to 23% of total revenue [1] Price Target and Valuation - Goldman Sachs set a 12-month price target of 109.6 HKD for WuXi AppTec's Hong Kong stock, based on a forward P/E ratio of 18 times, while the target price for its Shanghai stock is set at 105.6 RMB [1] Revenue Guidance - The management of WuXi AppTec raised its full-year revenue guidance for 2025 to 43.5 to 44 billion RMB, up from the previous guidance of 42.5 to 43.5 billion RMB [1] - The revenue growth guidance for continuing operations was also increased to 17% to 18% year-on-year, compared to the previous range of 13% to 17% [1] Profitability and Capital Expenditure - The adjusted net profit margin is expected to improve [1] - Third-quarter capital expenditures amounted to 1.47 billion RMB, with a total of 3.57 billion RMB for the first nine months [1] - The full-year capital expenditure budget has been revised down to 5.5 to 6 billion RMB from the previous estimate of 7 to 8 billion RMB due to longer-than-expected settlement periods for some projects [1] - Free cash flow guidance has been raised to 8 to 8.5 billion RMB, up from the previous range of 5 to 6 billion RMB [1] - Management reiterated its commitment to advancing global capacity construction [1]